Jupiter Neurosciences, Inc. income statement

In fiscal 2025, Jupiter Neurosciences, Inc. reported revenue of $21,796, operating income of −$8.9m (a -40873.2% margin) and net income of −$8.6m, or −$0.25 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Jupiter Neurosciences, Inc.: income statement, annual
Fiscal year	2024Dec 2024	2025Dec 2025
Revenue	0	22
Cost of revenue	—	4
Gross profit	—	18
Research and development	493	2,087
Selling, general and administrative	—	6,840
General and administrative	2,599	—
Operating income	−3,091	−8,909
Interest expense	248	66
Net income	−2,440	−8,645
Diluted EPS	−$0.08	−$0.25
Diluted shares (average)	29m	35m

US$ thousands unless shown otherwise. Fiscal quarters.

Jupiter Neurosciences, Inc.: income statement, quarterly
Quarter	2025 Q1Mar 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	0	19	24
Cost of revenue	—	4	3
Gross profit	—	14	21
Research and development	467	411	600
Selling, general and administrative	—	1,566	2,164
General and administrative	1,071	—	—
Operating income	−1,538	−1,963	−2,743
Interest expense	1	119	91
Net income	−1,529	−2,062	−2,274
Diluted EPS	−$0.05	−$4.50	−$4.08

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Jupiter Neurosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Jupiter Neurosciences, Inc.